Fibrin sealant: current and potential clinical applications

Area of Science:

• Biomaterials Science
• Hematology
• Surgical Innovation

Background:

• Limited well-controlled studies exist on fibrin sealant's clinical efficacy, particularly in trauma like liver lacerations.
• Current US fibrin sealants face challenges: cryoprecipitate lacks viral inactivation and has variable fibrinogen, while bovine thrombin lacks regulation for factor V content.
• Manufacturers are promoting fibrin sealants as alternatives to traditional bovine thrombin and cryoprecipitate.

Purpose of the Study:

• To highlight the need for better-controlled studies on fibrin sealant efficacy.
• To discuss the limitations of current fibrin sealant components and their regulatory oversight.
• To explore the development of clinically valid endpoints for evaluating commercial fibrin sealants.

Main Methods:

• Review of existing literature on fibrin sealant efficacy and limitations.
• Analysis of regulatory perspectives on defining efficacy endpoints.
• Discussion of potential future applications and formulations of fibrin sealants.

Main Results:

• Few studies adequately define fibrin sealant efficacy through metrics like lives saved or reduced transfusions.
• Regulatory agencies and manufacturers are beginning to establish standards for efficacy evaluation.
• Animal studies and surrogate endpoints (e.g., reduced factor concentrate use) may be considered for regulatory approval.

Conclusions:

• Further research is crucial to establish the clinical efficacy of fibrin sealants.
• New regulatory standards are being developed to ensure the safety and effectiveness of commercial fibrin sealants.
• Fibrin sealants hold promise for future applications, including as matrices for recombinant factors.